Results 41 to 50 of about 22,047 (159)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects

Clinical Pharmacology: Advances and Applications, 2013
Yimin Cui,1 Yan Song,2 Jessie Wang,2 Zhigang Yu,2 Alan Schuster,2 Yu Chen Barrett,2 Charles Frost2 1Peking University First Hospital, Beijing, People's Republic of China; 2Bristol-Myers Squibb, Princeton, NJ, USA Background: The pharmacokinetics (PK),
Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C   +6 more
doaj  

Reduced postoperative inflammation and blood loss after robotic arm‐assisted unicompartmental compared with total knee arthroplasty: A propensity score‐matched analysis

Knee Surgery, Sports Traumatology, Arthroscopy, EarlyView.
Abstract Purpose Robotic arm‐assisted unicompartmental knee arthroplasty (raUKA) offers potential advantages over robotic arm‐assisted total knee arthroplasty (raTKA), but its biological benefits remain unclear. Superior early recovery after raUKA may be related to reduced systemic inflammation and blood loss.
Dirk Müller, Florian Pohlig, Benjamin Schloßmacher, Vincent Lallinger, Michael T. Hirschmann, Rüdiger von Eisenhart‐Rothe, Igor Lazic   +6 more
wiley   +1 more source

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

Journal of Comparative Effectiveness Research, 2023
Aim: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. Methods: This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or ...
Josep Comin Colet, Antoni Sicras Mainar, Joel Salazar-Mendiguchia, Isabel del Campo Alonso, Ainara Echeto, David Vilanova Larena, Olga Delgado Sanchez   +6 more
doaj   +1 more source

Electronic monitoring of adherence to once‐daily and twice‐daily direct oral anticoagulants in patients with atrial fibrillation: Baseline data from the SMAAP‐AF trial

Journal of Arrhythmia, 2021
Background Nonadherence diminishes the efficacy of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (NVAF). This report presents the baseline survey results regarding medication adherence among NVAF patients who were ...
Tsuyoshi Shiga, Toshimi Kimura, Noritoshi Fukushima, Yuji Yoshiyama, Kazunori Iwade, Fumiaki Mori, Yoichi Ajiro, Shoji Haruta, Yuichiro Yamada, Emi Sawada, Nobuhisa Hagiwara, the SMAAP‐AF investigators   +11 more
doaj   +1 more source

Insights from a six‐year hair drug analysis compendium in drug‐facilitated crimes involving vulnerable population cases

Journal of Forensic Sciences, EarlyView.
Abstract Hair analysis is a well‐established matrix in forensic toxicology, offering a valuable alternative or complement to traditional matrices in diverse contexts, including drug‐facilitated crimes (DFC), elder abuse, and accidental exposure in children.
Amandine Fort, Coralie Boudin, Hélène Eysseric‐Guerin, Virginie Scolan, François Paysant, Cloé Scherpereel, Mélissa Revet, Françoise Stanke‐Labesque, Théo Willeman   +8 more
wiley   +1 more source

Development of Pacemaker Lead Thrombosis in a Patient with Atrial Fibrillation during Apixaban Treatment

Journal of Tehran University Heart Center, 2019
Apixaban was introduced in clinical use for nonvalvular atrial fibrillation as an alternative to warfarin. There is a dearth of information regarding apixaban use in patients suffering from atrial fibrillation with intracardiac foreign bodies such as ...
Adem Adar, Orhan Önalan, Fahri Cakan
doaj   +1 more source

Apixaban linearity profile for hydrotropic solubilization

BLDE University Journal of Health Sciences, 2020
A study on the hydrotropic solubility and linearity profile of Apixaban was carried out by using Sodium Salicylate as the solubilizing agent as Apixaban is poorly soluble in water.
Santosh Karajgi, Shripad Potadar
doaj   +1 more source

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

Clinical Pharmacology: Advances and Applications, 2013
Vijay V Upreti,1 Yan Song,1 Jessie Wang,2 Wonkyung Byon,3 Rebecca A Boyd,3 Janice M Pursley,4 Frank LaCreta,1 Charles E Frost1 1Clinical Pharmacology and Pharmacometrics, Discovery Medicine and Clinical Pharmacology, 2Exploratory Development Global ...
Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, LaCreta F, Frost CE   +7 more
doaj  

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, EarlyView.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source